|
|
 |
|
Viewing report
|
|
|
|
Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market
GBI Research, Aug 2010, Pages: 138
“Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors will Dominate the Market” provides in-depth analysis of unmet needs, drivers and barriers that impact the global men’s health market. The report analyzes the markets for men’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
The authors find that the men’s health market will continue to grow moderately. The prime reason for stagnancy will be the patent expiry of a top selling blockbuster, Viagra. The overall men’s health market is driven by the launch of late-stage pipeline candidates and the steady increase in prevalence and prescription population. The erectile dysfunction market controls a major portion of the men’s health market. In 2009 it accounted for 81% of the total men’s health market. Male hypogonadism accounts for 18% of the total market size. The premature ejaculation market represents a small portion of the total men’s health market. The premature ejaculation market has the highest level of unmet needs because it does not have any FDA approved products. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of new drugs in the near future. In 2009, the global men’s health market was estimated at $4,019m.
Scope
- Annualized market data for the men’s health market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism and premature ejaculation.
- Analysis of the men’s health market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.
- Market characterization of the men’s health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Abbott Laboratories, Endo-Pharmaceuticals Holding Inc., Janssen-Cilag EMEA, VIVUS Inc., Auxilium Pharmaceuticals, Inc., APP Pharmaceuticals, Inc, Columbia Laboratories, Inc., Watson Pharmaceuticals, Inc. and Valeant Pharmaceuticals International.
- Key M&A activities, licensing agreements, that have taken place in 2009 in the global men’s health market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Customers who bought this item also bought
Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues
Male Hypogonadism Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Transdermal Drug Delivery - Technologies, Markets, and Companies
Premature Ejaculation (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Premature Ejaculation - Pipeline Review, Q1 2011
Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
Global Erectile Dysfunction Drug Pipeline Capsule - 2012
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
|
|
|
|
